Erectile Dysfunction - Pipeline Review, H1 2019

Date: February 1, 2019
Pages: 109
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E49803E4C75EN
Leaflet:

Download PDF Leaflet

Erectile Dysfunction - Pipeline Review, H1 2019
Erectile Dysfunction - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 5, 7, 10, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns GlobalData requires using corporate email address.
Introduction
Erectile Dysfunction - Overview
Erectile Dysfunction - Therapeutics Development
Erectile Dysfunction - Therapeutics Assessment
Erectile Dysfunction - Companies Involved in Therapeutics Development
Erectile Dysfunction - Drug Profiles
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Erectile Dysfunction, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Erectile Dysfunction - Pipeline by Adamis Pharmaceuticals Corp, H1 2019
Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, H1 2019
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2019
Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, H1 2019
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2019
Erectile Dysfunction - Pipeline by Cure Pharmaceutical Inc, H1 2019
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2019
Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2019
Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2019
Erectile Dysfunction - Pipeline by Karessa Pharma Holding AB, H1 2019
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2019
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2019
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2019
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2019
Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H1 2019
Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, H1 2019
Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2019
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H1 2019
Erectile Dysfunction - Dormant Projects, H1 2019
Erectile Dysfunction - Dormant Projects, H1 2019 (Contd.1), H1 2019
Erectile Dysfunction - Dormant Projects, H1 2019 (Contd.2), H1 2019
Erectile Dysfunction - Discontinued Products, H1 2019

LIST OF FIGURES

Number of Products under Development for Erectile Dysfunction, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

Adamis Pharmaceuticals Corp
Aquestive Therapeutics Inc
Astellas Pharma Inc
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Cure Pharmaceutical Inc
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Humanetics Corp
Karessa Pharma Holding AB
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
NAL Pharmaceuticals Ltd
Pharmicell Co Ltd
SK Chemicals Co Ltd
Suda Pharmaceuticals Ltd
XuanZhu Pharma Co Ltd
Yangtze River Pharmaceutical Group
Skip to top


Erectile Dysfunction - Pipeline Insight, 2019 US$ 1,500.00 Jan, 2019 · 70 pages
Male Health Drug Development Pipeline Review, 2017 US$ 3,995.00 Sep, 2017 · 125 pages

Ask Your Question

Erectile Dysfunction - Pipeline Review, H1 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: